Download PowerPoint-Präsentation

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
Document related concepts
no text concepts found
Transcript 
• George D. Demetri
• Graduated: Stanford Medical School
• Residency: Univ. of Washington Hospitals
Internal Medicine
• Fellowship: Dana Farber Cancer Institute,
Hematology & Oncology, Boston
• Board certification Internal Medicine 1986
• Board certification Oncology 1989
• Professor of Medicine,Harvard Medical School
Director, Center of Sarcoma and Bone Oncology, DFCI
Director of the Ludwig Center
Senior Vice President of Experimental Therapeutics
• PubMed 265 publications
Drug development in sarcoma













Imatinib
Sunitinib
Regorafenib
Nilotinib
Retaspymicin
Ridaforolimus
Trabectedin
Tivantinib
Efatutazone
Conatumumab
Everolimus
CDK4 inhibitors
Dasatinib
flagship of innovation
in soft tissue sarcoma
George D. Demetri
• ‘Creative, high speed lab’
• George and Jaap Verweij wrote the protocol for phase III for
imatinib in metastatic GIST (SWOG-033 and EORTC 62005)
overnight from October 31 – November 1, 2000.
• This study marked the start of an intensified contact between
US and EU sarcoma researchers.
• Start of very much improved collaboration between US and
EORTC and for the setup of Worls´d SarcomaNetwork (WSN).
• Example of an international oriented researcher who will
always seek collaboration
• Surplus
Now and here
Related documents